Chronic Granulomatous Disease (CGD)
ACTIMMUNE® was studied in a randomized, double-blind, placebo-controlled study of 128 patients with different patterns of CGD inheritance.1 Patients ranged in age from 1 to 44 years, with the mean age being 14.6 years. The average duration of ACTIMMUNE® therapy was 8.9 months.
In this trial, ACTIMMUNE® reduced the relative risk of serious infections that required hospitalization or intravenous antibiotic treatment by 67%.1 After 12 months, 77% of patients receiving ACTIMMUNE® plus prophylactic antibiotics were free of serious infections, compared with 30% of patients receiving placebo.1
Time to serious infection1
Adapted from: : The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991;324:509-516.
ACTIMMUNE® reduced the number of patients experiencing at least one serious infection by 53%, compared with patients receiving the placebo. In addition, ACTIMMUNE® reduced the frequency of recurrent infections. There was a 64% reduction in the total number of serious infections in patients receiving ACTIMMUNE® compared with patients receiving placebo.
Patients with at least one serious infection1
Number of serious infections1
The most common adverse events associated with ACTIMMUNE® therapy included fever, headache, rash, and chills.
More Information
- Click here to learn more about ACTIMMUNE® safety in CGD treatment
The most common adverse events observed in patients with CGD were flu-like symptoms (e.g., headache, fatigue, fever, myalgia, and rigors). Similar adverse events were observed in patients with severe malignant osteopetrosis. Please refer to the ACTIMMUNE® Safety section on this Web site for more complete safety information.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of patients.
For U.S. resident use only. The product discussed herein may have different product labeling in different countries. Please see the full U.S. Prescribing Information (pdf file).
References
1. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon-γ to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324:509–516.
